LYPLA1 and neoplasm: The APT1 gene, LYPLA1, is amplified across a wide variety of tumor types, including 31.8%, 23.2% and 13.8%, in neuroendocrine prostate cancer, uterine carcinosarcoma and invasive breast carcinoma, respectively.